K-9 Immunity™ is an orally administered Complementary Medicine (class Dietary Supplement in the United States) intended for daily use in adult dogs undergoing conventional therapy, to assist in optimizing immune system function. It consists of a heterogeneous mixture of multiple heteropolysaccharide moieties derived from several species of well-known medicinal mushrooms.

The primary types of heteropolysaccharides found in K-9 Immunity™ are different structural arrangements of long chain, high molecular weight, right-hand triple helix structure, primarily with 1-3 beta-linked main chain formation. The main chain compositions are primarily composed of d-glucose and d-mannose, with greater and lesser degrees of alpha and beta linked side chain branching. The side branches contain a number of different five and six carbon sugars such as arabinose, xylose, fucose, fructose, mannose and glucose, with and without attached polypeptides and proteins. These heteropolysaccharides and polysaccharide-protein [glycoprotein] complexes are hot water soluble and ethanol insoluble.

Each Red and White size 0 capsule contains 500 mg pure heteropolysaccharide extract, with no added binders, fillers, flow enhancers or time release agents.

 

CLINICAL PHARMACOLOGY

K-9 Immunity™ is a dietary supplement of considerable pharmacological potential. While the exact mechanisms of action are only partly understood, the main actions exhibited by the mushroom derived polysaccharide and proteoglycan components appear to be activation and enhancement of various aspects of the innate and specific immune response [Host Mediated Immune Response]. The number and activity of T lymphocytes (T-cells), B lymphocytes (B-cells), macrophages and antigen presenting cells (APC) are stimulated and/or modulated. This immune system activation is thought to be accomplished by binding of the beta-glucans, proteoglycans and other heteropolysaccharides to a specific cellular receptor known as the complement receptor type 3 or CR3 on the surface of the various immune cells.

 

CLINICAL STUDIES AND MANUFACTURERS OBSERVATION
K-9 Immunity™ has been used in over 8500 canine cancer patients to date (August 2006) and the manufacturer’s observations have been overwhelmingly positive in regards to clinical outcome. While cancer is one of the most serious of all diseases for the medical and veterinary profession to face, it seems that most patients experience a greater quality of life, longer remission status and overall greater effective response to other therapies when using K-9 Immunity™ than those patients not receiving it.

There have been few proper, controlled studies conducted on canine cancers using the heteropolysaccharide class of immune modulators. However, there is a wealth of clinical data derived from trials using this class of compound as an adjunct to conventional therapy for treatment of cancer in humans. While this data certainly does not transfer across species lines directly, it is believed by many researchers that most of the mechanisms of action in the development and remission of cancers are identical (or at least substantially similar) between humans and canines. If anything, canines seem to respond better to immunomodulation therapy than do humans. For detailed research on this mechanism of therapy, please contact our research department at 775-886-6300, or use the “CONTACT US” link to send your request. We are happy to work with veterinarians in guiding the use of this approach in canine cancer cases, or referring you to veterinarians in your area who are familiar with this method of therapy.

 

INDICATIONS

K-9 Immunity™ is indicated as a daily supplements for use in adult dogs to help offset the side effects of chemotherapy, and for the avoidance of opportunistic infections associated with conventional cancer treatments. K-9 Immunity™ is used primarily as an adjunct to conventional chemo- and radiation therapy in canine patients undergoing treatment for cancer. This supplement can be used on a daily basis for long periods of time in otherwise healthy adult canine cancer patients, which can result in an overall lower incidence of treatment side effects and enhancement of quality of life parameters, through its well proven immunomodulating effect.

 

CONTRAINDICATIONS
K-9 Immunity™ has no known contraindications in canines.

 

PRECAUTIONS
The use of K-9 Immunity™ has been shown to lower abnormally high blood sugar levels and appears to increase the efficacy of insulin and oral anti-diabetic drugs. Care should be used in diabetic canines, and the dosage of insulin or oral anti-diabetic drugs may need to be adjusted accordingly.

 

USE IN PREGNANCY AND LACTATION
Safety and efficacy has not been evaluated in pregnancy or lactation or in puppies under 1 yr. age. Caution and careful observation should be used in these cases.

 

FOOD AND DRUG INTERACTIONS
There are no known drug interactions besides those associated with increased insulin sensitivity in diabetic patients as noted above.

 

WARNINGS

K-9 Immunity™ is primarily used as a daily supplement in seriously ill canine patients, and the caregivers should by counseled that immuno-modulation therapy alone may not be the best choice for treating their dog’s condition. Likewise, the attending veterinarian should realize that this supplement is intended to augment and enhance other therapeutic strategies, and K-9 Immunity™ by itself is not intended as a stand alone therapy, unless there are no other appropriate treatment options available.

 

ADVERSE REACTIONS
There have been no adverse reactions noted with K-9 Immunity™. An Allergic reaction is always possible with this and all other biologically active agents. If an allergic  reaction is suspected, stop the supplement immediately and contact your veterinarian or the manufacturer at 775-886-6300

 

OVERDOSAGE

There have been no known incidences of overdosage of K-9 Immunity™ . The acute and chronic safety of this supplement has been tested at dosages up to 1000 times the daily recommended dosage and no incidence of toxicity has been noted. K-9 Immunity™ is well tolerated and non-toxic.

 

DOSAGE AND ADMINISTRATION

During active cancer therapy and 7 days pre/post surgically, 500 mg of K-9 Immunity™ per 10 lbs body weight per day, taken with meals is recommended. (one capsule per ten pounds per day) As an adjunct to antibiotic therapy, 500 mg per 20 lbs body weight per day is indicated for the duration of the therapy plus and additional 1 week after antibiotic therapy has stopped. For general immune support and avoidance of cancer recurrence after the patient is clear of all signs of cancer, 500 mg per 20 lbs body weight per day of K-9 Immunity™ with meals is recommended. A Transfer Factor product such as bovine colostrums or avian source Transfer Factor is recommended co-administered as an adjunct with the K-9 Immunity™, as this can enhances the bioavalability and thereby the effectiveness of the heteropolysaccharides immune modulator compounds. The daily dosage may be administered once daily or divided into multiple doses with equal effectiveness.

 
HOW SUPPLIED
K-9 Immunity™ comes in bottles of 84, red and white colored, capsules of 500 mg each.

As with all medications, keep out of the reach of children

 

Available in Canada From
The Immunoceuticals Company,
3888 Northwest Road, Denman Island,
BC, Canada, V0R1T0
(Toll Free - 877 Rx Aloha - (877- 792-5642)
250-335-0713
sales@alohamedicinals.ca
www.alohamedicinals.ca
www.dogcancer.ca

 

MANUFACTURED BY

Aloha Medicinals Inc.
2300 Arrowhead Dr.
Carson City NV 89706

FDA # 17740188636
South Africa Registration # 003925
Australia AQIS Registration # 200603575

 

For telephone orders, please call — Toll Free 1-877-792 5642
For customer care, please call 1-250-335-0265
Every Day, 8AM to 5PM PST.

 

Bookmark this page into your favorite bookmark manager. Or press (CTRL-D)